<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028780</url>
  </required_header>
  <id_info>
    <org_study_id>1321.5</org_study_id>
    <nct_id>NCT02028780</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects</brief_title>
  <official_title>Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI
      655075 following intravenous administration of single rising doses of BI 655075 when
      administered alone and after administration of dabigatran.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Drug-related Adverse Events in Part 1 and Part 2</measure>
    <time_frame>From first drug administration until 13 weeks after the last drug administration, upto 98 days (Part-I) &amp; upto 108 days (Part-II)</time_frame>
    <description>Percentage of subjects with drug-related adverse events in Part 1 and Part 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ae0−74,ss on Days 4 and 11 for Sum Dabigatran (Part II)</measure>
    <time_frame>0-2 h, 2-6 h, 6-10 h, 10-12 h,12-14h, 14-26 h, 26-50 h, 50-74 h after drug administration of dabigatran etexilate on Day 4 and Day 11.</time_frame>
    <description>Amount of analyte eliminated in urine at steady state from the time point 0 hours to time point 74 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC2-12,ss on Days 4 and 11 for Unbound Sum Dabigatran (Part II).</measure>
    <time_frame>Day 4 (Part I) and Day 11 (Part II). Time frame are provided in detail in the Description section</time_frame>
    <description>Area under the concentration-time curve of the dabigatran in plasma at steady state over the time interval 2 hours-12 hours.
Time Frame: For dose group 5 to 7 (Day 1 to 3-Part-I):74hours (h), 74.5h, 75h, 76h, 78h, 80h, 82h, 84h, For dose group 8 (Day 1 to 3-Part-I): 74h, 74.5h, 75h, 76h, 78h, 80h, 82h, 84h and For dose group 5-7 (Day11 to Day13-Part II):242h, 242.167h, 242.5h, 243h, 244h,246h, 248h, 250h, 252h. For dose group 8 (Day11 to Day13-Part II):242h, 242.083h, 242.25h, 242.333h, 243.333h, 244h, 246h, 248h, 252h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for Idarucizumab in the Part I &amp; Part II.</measure>
    <time_frame>Day 1 to 3 (Part I) and Day 11 to 13 (Part II); Time frame are provided in detail in the Description section</time_frame>
    <description>Maximum measured concentration of the analyte in plasma for idarucizumab Time frame: For dose group 1 to 3 (Day 1 to 3-Part-I): predose, 0 (end of infusion), 0.033h, 0.083h, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h. For dose group 4 (Day 1 to 3-Part-I): predose, −0.5h, 0 (end of infusion), 0.033h, 0.083h, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 48h. For dose group 5-7 (Day11 to Day13-Part II): predose, 242h (end of infusion), 242.033h, 242.083h, 242.167h, 242.25h, 242.5h, 242.75h, 243h, 243.5h, 244h, 244.5h, 245h, 246h, 248h, 250h, 252h, 254h, 258h, 266h, 290h.For dose group 8 (day11 to Day13-Part II): predose, 242h (end of infusion), 242.083h, 242.25h, 242.333h, 242.367h, 242.5h, 242.833h, 243.333h, 244h, 245h, 246h, 248h, 252h, 254h, 266h, 290h, 314h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf for Idarucizumab in the Part I &amp; Part II.</measure>
    <time_frame>Day 1 to 3 (Part I) and Day 11 to 13 (Part II); Time frame are provided in detail in the Description section</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma for idarucizumab over the time interval from 0 extrapolated to infinity.
Time frame: For dose group 1 to 3 (Day 1 to 3-Part-I): predose, 0 (end of infusion), 0.033h, 0.083, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h. For dose group 4 (Day 1 to 3-Part-I): predose, −0.5h, 0 (end of infusion), 0.033h, 0.083h, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 48h. For dose group 5-7 (Day11 to Day13-Part II): predose, 242h (end of infusion), 242.033h, 242.083h, 242.167h, 242.25h, 242.5h, 242.75h, 243h, 243.5h, 244h, 244.5h, 245h, 246h, 248h, 250h, 252h, 254h, 258h, 266h, 290h.For dose group 8 (day11 to Day13-Part II): predose, 242h (end of infusion), 242.083h, 242.25h, 242.333h, 242.367h, 242.5h, 242.833h, 243.333h, 244h, 245h, 246h, 248h, 252h, 254h, 266h, 290h, 314h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-72 for Idarucizumab in the Part I &amp; Part II.</measure>
    <time_frame>Day 1 to 4 (Part I) and Day 11 to 14 (Part II); Time frame are provided in detail in the Description section</time_frame>
    <description>Amount of idarucizumab eliminated in urine over the time interval 0-72. Time frame: For dose groups 1 to 3 (day1 to day4-Part-1):0-4 h, 4-8 h, 8-12 h, 12-24 h, 24-48 h, 48-72 h. For dose groups 5 to 7 (day 11 to day14-Part-II): 0-4 h, 4-8 h, 8-10 h, 10-12 h,12-24 h, 24-48 h, and 48-72 h. For dose groups 8 (day11 to day14-Part-II): 0-4h, 4-8 h, 8-10 h, 10-24 h, 24-48 h, 48-72 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-73 for the Dose Group 4 in the Part I</measure>
    <time_frame>For dose group 4 (day1 to day4-Part-1): 0-7h, 7-13h, 13-25h, 25-49h, 49-73h</time_frame>
    <description>Amount of the analyte excreted in urine over the time interval 0-73</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC2-12</measure>
    <time_frame>Day 4 and Day 11 (Part II); Time frame are provided in detail in the Description section</time_frame>
    <description>Area under the effect curve over the time interval from 2 to 12h, AUEC2-12 on Days 4 and 11 for diluted thrombin time (dTT).
For dose groups 5 to 7(day4-Part-II): 74h, 74.5h, 75h, 76h, 78h, 80h, 82h, 84h on day 4. For dose groups 5 to 7(day11-Part-II): 242h, 242.083h, 242.167h, 242.5h, 243h, 244h, 246h, 248h, 250h, 252h. For dose groups 8(day4-Part-II): 74.5 h, 78 h, 84 h on day 4. For dose groups 8(day11-Part-II): 242h, 242.083h,242.25h, 242.333h, 243.333h, 244h, 246h, 248h, 252h on day 11.
AUEC is calculated by multiplying the ratio (Value at each time point/Ebase, unit of Vaue is [s] and Ebase is value [s] at baseline) by time. Therefore, Unit for AUEC2-12 is [h].</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Idarucizumab single doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>different infusion durations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Idarucizumab with dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>short infusion with 2 capsules dabigatran</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to dose</intervention_name>
    <description>placebo</description>
    <arm_group_label>Idarucizumab single doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarucizumab</intervention_name>
    <description>short infusion</description>
    <arm_group_label>Idarucizumab with dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Idarucizumab</intervention_name>
    <description>Placebo to Idarucizumab</description>
    <arm_group_label>Idarucizumab with dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran</intervention_name>
    <description>2 capsules dabigatran</description>
    <arm_group_label>Idarucizumab with dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarucizumab</intervention_name>
    <description>short infusion</description>
    <arm_group_label>Idarucizumab single doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy Japanese male subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1321.5.00001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sumida-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <results_first_submitted>November 13, 2015</results_first_submitted>
  <results_first_submitted_qc>January 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2016</results_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Randomised, double-blind within dose groups, placebo controlled, sequential rising order, single centre trial. This study has two phases ie., Observation phase (Single administration of placebo or BI study drug and 6-14 days follow up) and Follow up phase (End of observation phase to 92-98 days after administration of Placebo or BI study drug).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo_5m (Part I)</title>
          <description>Subject received a single intravenous infusion of matching placebo to idarucizumab once daily for 5min on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Placebo_1h (Part I)</title>
          <description>Subject received a single intravenous infusion of matching placebo to idarucizumab once daily for 1h (hour) on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>BI1000mg_5m (Dose group1 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 1000mg for 5min on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>BI2000mg_5m (Dose group2 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 2000mg for 5min on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>BI4000mg_5m (Dose group3 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 4000mg for 5min on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>BI8000mg_1h (Dose group4 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 8000mg for 1h on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>DE+Placebo_5m (Part II)</title>
          <description>Subject received a multiple oral doses of dabigatran etexilate 220 mg twice daily(b.i.d.) from Days 1 to 3 and once daily(q.d)on Day 4 and from Days 8 to 10 and once daily(q.d)on Day 11,followed with a single intravenous infusion of matching placebo to idarucizumab for 5min, approximately 2h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="P8">
          <title>DE+Placebo+Placebo (Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d. from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of two doses of matching placebo to Idarucizumab for 5 min + 5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="P9">
          <title>DE+1000mg_5m (Dose group5 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="P10">
          <title>DE+2000mg_5m (Dose group6 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="P11">
          <title>DE+4000mg_5m (Dose group7 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="P12">
          <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Observation Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): : This subject set included all subjects who received the idarucizumab or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo_5m (Part I)</title>
          <description>Subject received a single intravenous infusion of matching placebo to idarucizumab once daily for 5min on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Placebo_1h (Part I)</title>
          <description>Subject received a single intravenous infusion of matching placebo to idarucizumab once daily for 1h (hour) on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>BI1000mg_5m (Dose group1 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 1000mg for 5min on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>BI2000mg_5m (Dose group2 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 2000mg for 5min on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>BI4000mg_5m (Dose group3 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 4000mg for 5min on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>BI8000mg_1h (Dose group4 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 8000mg for 1h on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>DE+Placebo_5m (Part II)</title>
          <description>Subject received a multiple oral doses of dabigatran etexilate 220 mg twice daily(b.i.d.) from Days 1 to 3 and once daily(q.d)on Day 4 and from Days 8 to 10 and once daily(q.d)on Day 11,followed with a single intravenous infusion of matching placebo to idarucizumab for 5min, approximately 2h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="B8">
          <title>DE+Placebo+Placebo (Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d. from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of two doses of matching placebo to Idarucizumab for 5 min + 5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="B9">
          <title>DE+1000mg_5m (Dose group5 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="B10">
          <title>DE+2000mg_5m (Dose group6 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="B11">
          <title>DE+4000mg_5m (Dose group7 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="B12">
          <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="9"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="9"/>
            <count group_id="B10" value="9"/>
            <count group_id="B11" value="9"/>
            <count group_id="B12" value="9"/>
            <count group_id="B13" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="10.5"/>
                    <measurement group_id="B2" value="32.5" spread="4.9"/>
                    <measurement group_id="B3" value="31.5" spread="10.9"/>
                    <measurement group_id="B4" value="27.8" spread="7.7"/>
                    <measurement group_id="B5" value="31.5" spread="8.3"/>
                    <measurement group_id="B6" value="32.2" spread="8.1"/>
                    <measurement group_id="B7" value="24.7" spread="3.3"/>
                    <measurement group_id="B8" value="29.7" spread="5.0"/>
                    <measurement group_id="B9" value="23.8" spread="3.1"/>
                    <measurement group_id="B10" value="25.7" spread="3.1"/>
                    <measurement group_id="B11" value="25.4" spread="2.7"/>
                    <measurement group_id="B12" value="24.4" spread="1.4"/>
                    <measurement group_id="B13" value="27.3" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="9"/>
                    <measurement group_id="B12" value="9"/>
                    <measurement group_id="B13" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Drug-related Adverse Events in Part 1 and Part 2</title>
        <description>Percentage of subjects with drug-related adverse events in Part 1 and Part 2.</description>
        <time_frame>From first drug administration until 13 weeks after the last drug administration, upto 98 days (Part-I) &amp; upto 108 days (Part-II)</time_frame>
        <population>Treated set (TS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo_5m (Part I)</title>
            <description>Subject received a single intravenous infusion of matching placebo to idarucizumab once daily for 5min on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo_1h (Part I)</title>
            <description>Subject received a single intravenous infusion of matching placebo to idarucizumab once daily for 1h (hour) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>BI1000mg_5m (Dose group1 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 1000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>BI2000mg_5m (Dose group2 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 2000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>BI4000mg_5m (Dose group3 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 4000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>BI8000mg_1h (Dose group4 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 8000mg for 1h on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>DE+Placebo_5m (Part II)</title>
            <description>Subject received a multiple oral doses of dabigatran etexilate 220 mg twice daily(b.i.d.) from Days 1 to 3 and once daily(q.d)on Day 4 and from Days 8 to 10 and once daily(q.d)on Day 11,followed with a single intravenous infusion of matching placebo to idarucizumab for 5min, approximately 2h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O8">
            <title>DE+Placebo+Placebo (Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d. from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of two doses of matching placebo to Idarucizumab for 5 min + 5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O9">
            <title>DE+1000mg_5m (Dose group5 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O10">
            <title>DE+2000mg_5m (Dose group6 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O11">
            <title>DE+4000mg_5m (Dose group7 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O12">
            <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Drug-related Adverse Events in Part 1 and Part 2</title>
          <description>Percentage of subjects with drug-related adverse events in Part 1 and Part 2.</description>
          <population>Treated set (TS)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="0.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                    <measurement group_id="O12" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae0−74,ss on Days 4 and 11 for Sum Dabigatran (Part II)</title>
        <description>Amount of analyte eliminated in urine at steady state from the time point 0 hours to time point 74 hours.</description>
        <time_frame>0–2 h, 2–6 h, 6–10 h, 10–12 h,12–14h, 14-26 h, 26-50 h, 50-74 h after drug administration of dabigatran etexilate on Day 4 and Day 11.</time_frame>
        <population>PKS set: This subject set included all subjects who received the idarucizumab and who had at least one pharmacokinetic parameter. For the Part 2, subjects who had the emesis with onset at or before twice the median tmax of dabigatran were not included in this set.</population>
        <group_list>
          <group group_id="O1">
            <title>DE+Placebo_5m (Part II)</title>
            <description>Subject received a multiple oral doses of dabigatran etexilate 220 mg twice daily(b.i.d.) from Days 1 to 3 and once daily(q.d)on Day 4 and from Days 8 to 10 and once daily(q.d)on Day 11,followed with a single intravenous infusion of matching placebo to idarucizumab for 5min, approximately 2h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O2">
            <title>DE+1000mg_5m (Dose group5 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O3">
            <title>DE+2000mg_5m (Dose group6 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O4">
            <title>DE+4000mg_5m (Dose group7 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O5">
            <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae0−74,ss on Days 4 and 11 for Sum Dabigatran (Part II)</title>
          <description>Amount of analyte eliminated in urine at steady state from the time point 0 hours to time point 74 hours.</description>
          <population>PKS set: This subject set included all subjects who received the idarucizumab and who had at least one pharmacokinetic parameter. For the Part 2, subjects who had the emesis with onset at or before twice the median tmax of dabigatran were not included in this set.</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9250" spread="42.0"/>
                    <measurement group_id="O2" value="12800" spread="21.6"/>
                    <measurement group_id="O3" value="11700" spread="45.7"/>
                    <measurement group_id="O4" value="8810" spread="33.8"/>
                    <measurement group_id="O5" value="11000" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9690" spread="27.7"/>
                    <measurement group_id="O2" value="12500" spread="32.0"/>
                    <measurement group_id="O3" value="13100" spread="30.1"/>
                    <measurement group_id="O4" value="9310" spread="41.0"/>
                    <measurement group_id="O5" value="10600" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC2-12,ss on Days 4 and 11 for Unbound Sum Dabigatran (Part II).</title>
        <description>Area under the concentration-time curve of the dabigatran in plasma at steady state over the time interval 2 hours-12 hours.
Time Frame: For dose group 5 to 7 (Day 1 to 3-Part-I):74hours (h), 74.5h, 75h, 76h, 78h, 80h, 82h, 84h, For dose group 8 (Day 1 to 3-Part-I): 74h, 74.5h, 75h, 76h, 78h, 80h, 82h, 84h and For dose group 5-7 (Day11 to Day13-Part II):242h, 242.167h, 242.5h, 243h, 244h,246h, 248h, 250h, 252h. For dose group 8 (Day11 to Day13-Part II):242h, 242.083h, 242.25h, 242.333h, 243.333h, 244h, 246h, 248h, 252h.</description>
        <time_frame>Day 4 (Part I) and Day 11 (Part II). Time frame are provided in detail in the Description section</time_frame>
        <population>PKS set</population>
        <group_list>
          <group group_id="O1">
            <title>DE+Placebo_5m (Part II)</title>
            <description>Subject received a multiple oral doses of dabigatran etexilate 220 mg twice daily(b.i.d.) from Days 1 to 3 and once daily(q.d)on Day 4 and from Days 8 to 10 and once daily(q.d)on Day 11,followed with a single intravenous infusion of matching placebo to idarucizumab for 5min, approximately 2h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O2">
            <title>DE+1000mg_5m (Dose group5 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O3">
            <title>DE+2000mg_5m (Dose group6 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O4">
            <title>DE+4000mg_5m (Dose group7 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O5">
            <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC2-12,ss on Days 4 and 11 for Unbound Sum Dabigatran (Part II).</title>
          <description>Area under the concentration-time curve of the dabigatran in plasma at steady state over the time interval 2 hours-12 hours.
Time Frame: For dose group 5 to 7 (Day 1 to 3-Part-I):74hours (h), 74.5h, 75h, 76h, 78h, 80h, 82h, 84h, For dose group 8 (Day 1 to 3-Part-I): 74h, 74.5h, 75h, 76h, 78h, 80h, 82h, 84h and For dose group 5-7 (Day11 to Day13-Part II):242h, 242.167h, 242.5h, 243h, 244h,246h, 248h, 250h, 252h. For dose group 8 (Day11 to Day13-Part II):242h, 242.083h, 242.25h, 242.333h, 243.333h, 244h, 246h, 248h, 252h.</description>
          <population>PKS set</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="909" spread="56.2"/>
                    <measurement group_id="O2" value="1260" spread="25.0"/>
                    <measurement group_id="O3" value="1010" spread="54.1"/>
                    <measurement group_id="O4" value="802" spread="46.8"/>
                    <measurement group_id="O5" value="1100" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="909" spread="34.8"/>
                    <measurement group_id="O2" value="330" spread="109"/>
                    <measurement group_id="O3" value="82.2" spread="149"/>
                    <measurement group_id="O4" value="10.1" spread="1.86"/>
                    <measurement group_id="O5" value="10.0" spread="0.0213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax for Idarucizumab in the Part I &amp; Part II.</title>
        <description>Maximum measured concentration of the analyte in plasma for idarucizumab Time frame: For dose group 1 to 3 (Day 1 to 3-Part-I): predose, 0 (end of infusion), 0.033h, 0.083h, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h. For dose group 4 (Day 1 to 3-Part-I): predose, −0.5h, 0 (end of infusion), 0.033h, 0.083h, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 48h. For dose group 5-7 (Day11 to Day13-Part II): predose, 242h (end of infusion), 242.033h, 242.083h, 242.167h, 242.25h, 242.5h, 242.75h, 243h, 243.5h, 244h, 244.5h, 245h, 246h, 248h, 250h, 252h, 254h, 258h, 266h, 290h.For dose group 8 (day11 to Day13-Part II): predose, 242h (end of infusion), 242.083h, 242.25h, 242.333h, 242.367h, 242.5h, 242.833h, 243.333h, 244h, 245h, 246h, 248h, 252h, 254h, 266h, 290h, 314h.</description>
        <time_frame>Day 1 to 3 (Part I) and Day 11 to 13 (Part II); Time frame are provided in detail in the Description section</time_frame>
        <population>PKS set</population>
        <group_list>
          <group group_id="O1">
            <title>BI1000mg_5m (Dose group1 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 1000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>BI2000mg_5m (Dose group2 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 2000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>BI4000mg_5m (Dose group3 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 4000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>BI8000mg_1h (Dose group4 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 8000mg for 1h on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>DE+1000mg_5m (Dose group5 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O6">
            <title>DE+2000mg_5m (Dose group6 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O7">
            <title>DE+4000mg_5m (Dose group7 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O8">
            <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Idarucizumab in the Part I &amp; Part II.</title>
          <description>Maximum measured concentration of the analyte in plasma for idarucizumab Time frame: For dose group 1 to 3 (Day 1 to 3-Part-I): predose, 0 (end of infusion), 0.033h, 0.083h, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h. For dose group 4 (Day 1 to 3-Part-I): predose, −0.5h, 0 (end of infusion), 0.033h, 0.083h, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 48h. For dose group 5-7 (Day11 to Day13-Part II): predose, 242h (end of infusion), 242.033h, 242.083h, 242.167h, 242.25h, 242.5h, 242.75h, 243h, 243.5h, 244h, 244.5h, 245h, 246h, 248h, 250h, 252h, 254h, 258h, 266h, 290h.For dose group 8 (day11 to Day13-Part II): predose, 242h (end of infusion), 242.083h, 242.25h, 242.333h, 242.367h, 242.5h, 242.833h, 243.333h, 244h, 245h, 246h, 248h, 252h, 254h, 266h, 290h, 314h.</description>
          <population>PKS set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6810" spread="10.1"/>
                    <measurement group_id="O2" value="15700" spread="10.9"/>
                    <measurement group_id="O3" value="28100" spread="14.3"/>
                    <measurement group_id="O4" value="37600" spread="6.88"/>
                    <measurement group_id="O5" value="9510" spread="33.8"/>
                    <measurement group_id="O6" value="17600" spread="16.8"/>
                    <measurement group_id="O7" value="30200" spread="17.7"/>
                    <measurement group_id="O8" value="30100" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf for Idarucizumab in the Part I &amp; Part II.</title>
        <description>Area under the concentration-time curve of the analyte in plasma for idarucizumab over the time interval from 0 extrapolated to infinity.
Time frame: For dose group 1 to 3 (Day 1 to 3-Part-I): predose, 0 (end of infusion), 0.033h, 0.083, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h. For dose group 4 (Day 1 to 3-Part-I): predose, −0.5h, 0 (end of infusion), 0.033h, 0.083h, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 48h. For dose group 5-7 (Day11 to Day13-Part II): predose, 242h (end of infusion), 242.033h, 242.083h, 242.167h, 242.25h, 242.5h, 242.75h, 243h, 243.5h, 244h, 244.5h, 245h, 246h, 248h, 250h, 252h, 254h, 258h, 266h, 290h.For dose group 8 (day11 to Day13-Part II): predose, 242h (end of infusion), 242.083h, 242.25h, 242.333h, 242.367h, 242.5h, 242.833h, 243.333h, 244h, 245h, 246h, 248h, 252h, 254h, 266h, 290h, 314h.</description>
        <time_frame>Day 1 to 3 (Part I) and Day 11 to 13 (Part II); Time frame are provided in detail in the Description section</time_frame>
        <population>PKS set</population>
        <group_list>
          <group group_id="O1">
            <title>BI1000mg_5m (Dose group1 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 1000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>BI2000mg_5m (Dose group2 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 2000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>BI4000mg_5m (Dose group3 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 4000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>BI8000mg_1h (Dose group4 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 8000mg for 1h on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>DE+1000mg_5m (Dose group5 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O6">
            <title>DE+2000mg_5m (Dose group6 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O7">
            <title>DE+4000mg_5m (Dose group7 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O8">
            <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf for Idarucizumab in the Part I &amp; Part II.</title>
          <description>Area under the concentration-time curve of the analyte in plasma for idarucizumab over the time interval from 0 extrapolated to infinity.
Time frame: For dose group 1 to 3 (Day 1 to 3-Part-I): predose, 0 (end of infusion), 0.033h, 0.083, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 48h. For dose group 4 (Day 1 to 3-Part-I): predose, −0.5h, 0 (end of infusion), 0.033h, 0.083h, 0.167h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 16h, 24h, 48h. For dose group 5-7 (Day11 to Day13-Part II): predose, 242h (end of infusion), 242.033h, 242.083h, 242.167h, 242.25h, 242.5h, 242.75h, 243h, 243.5h, 244h, 244.5h, 245h, 246h, 248h, 250h, 252h, 254h, 258h, 266h, 290h.For dose group 8 (day11 to Day13-Part II): predose, 242h (end of infusion), 242.083h, 242.25h, 242.333h, 242.367h, 242.5h, 242.833h, 243.333h, 244h, 245h, 246h, 248h, 252h, 254h, 266h, 290h, 314h.</description>
          <population>PKS set</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9150" spread="15.0"/>
                    <measurement group_id="O2" value="19500" spread="17.8"/>
                    <measurement group_id="O3" value="37600" spread="14.4"/>
                    <measurement group_id="O4" value="76800" spread="14.8"/>
                    <measurement group_id="O5" value="8590" spread="14.2"/>
                    <measurement group_id="O6" value="19200" spread="18.5"/>
                    <measurement group_id="O7" value="34500" spread="16.6"/>
                    <measurement group_id="O8" value="43300" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae0-72 for Idarucizumab in the Part I &amp; Part II.</title>
        <description>Amount of idarucizumab eliminated in urine over the time interval 0-72. Time frame: For dose groups 1 to 3 (day1 to day4-Part-1):0–4 h, 4–8 h, 8–12 h, 12–24 h, 24–48 h, 48–72 h. For dose groups 5 to 7 (day 11 to day14-Part-II): 0-4 h, 4–8 h, 8–10 h, 10–12 h,12–24 h, 24–48 h, and 48–72 h. For dose groups 8 (day11 to day14-Part-II): 0-4h, 4–8 h, 8–10 h, 10–24 h, 24–48 h, 48–72 h.</description>
        <time_frame>Day 1 to 4 (Part I) and Day 11 to 14 (Part II); Time frame are provided in detail in the Description section</time_frame>
        <population>PKS set. Ae 0-72 data is not available for BI8000mg_1h (Dose group 4 - Part I) due to longer infusion time resulting different urine collection interval. Instead, Ae 0-73 is presented for BI8000mg_1h as separate endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>BI1000mg_5m (Dose group1 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 1000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>BI2000mg_5m (Dose group2 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 2000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>BI4000mg_5m (Dose group3 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 4000mg for 5min on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>DE+1000mg_5m (Dose group5 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O5">
            <title>DE+2000mg_5m (Dose group6 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O6">
            <title>DE+4000mg_5m (Dose group7 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O7">
            <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae0-72 for Idarucizumab in the Part I &amp; Part II.</title>
          <description>Amount of idarucizumab eliminated in urine over the time interval 0-72. Time frame: For dose groups 1 to 3 (day1 to day4-Part-1):0–4 h, 4–8 h, 8–12 h, 12–24 h, 24–48 h, 48–72 h. For dose groups 5 to 7 (day 11 to day14-Part-II): 0-4 h, 4–8 h, 8–10 h, 10–12 h,12–24 h, 24–48 h, and 48–72 h. For dose groups 8 (day11 to day14-Part-II): 0-4h, 4–8 h, 8–10 h, 10–24 h, 24–48 h, 48–72 h.</description>
          <population>PKS set. Ae 0-72 data is not available for BI8000mg_1h (Dose group 4 - Part I) due to longer infusion time resulting different urine collection interval. Instead, Ae 0-73 is presented for BI8000mg_1h as separate endpoint.</population>
          <units>μmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="54.9"/>
                    <measurement group_id="O2" value="6.10" spread="165"/>
                    <measurement group_id="O3" value="20.5" spread="52.4"/>
                    <measurement group_id="O4" value="4.21" spread="35.1"/>
                    <measurement group_id="O5" value="13.8" spread="12.5"/>
                    <measurement group_id="O6" value="42.6" spread="16.4"/>
                    <measurement group_id="O7" value="51.5" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae0-73 for the Dose Group 4 in the Part I</title>
        <description>Amount of the analyte excreted in urine over the time interval 0-73</description>
        <time_frame>For dose group 4 (day1 to day4-Part-1): 0-7h, 7-13h, 13-25h, 25-49h, 49-73h</time_frame>
        <population>PKS set. The results from dose group 4 has been disclosed, because only dose group 4 had 1hr infusion, Ae 0-73 was reported, instead of Ae0-72.</population>
        <group_list>
          <group group_id="O1">
            <title>BI8000mg_1h (Dose group4 - Part I)</title>
            <description>Subject received a single intravenous infusion of idarucizumab 8000mg for 1h on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Ae0-73 for the Dose Group 4 in the Part I</title>
          <description>Amount of the analyte excreted in urine over the time interval 0-73</description>
          <population>PKS set. The results from dose group 4 has been disclosed, because only dose group 4 had 1hr infusion, Ae 0-73 was reported, instead of Ae0-72.</population>
          <units>μmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUEC2-12</title>
        <description>Area under the effect curve over the time interval from 2 to 12h, AUEC2-12 on Days 4 and 11 for diluted thrombin time (dTT).
For dose groups 5 to 7(day4-Part-II): 74h, 74.5h, 75h, 76h, 78h, 80h, 82h, 84h on day 4. For dose groups 5 to 7(day11-Part-II): 242h, 242.083h, 242.167h, 242.5h, 243h, 244h, 246h, 248h, 250h, 252h. For dose groups 8(day4-Part-II): 74.5 h, 78 h, 84 h on day 4. For dose groups 8(day11-Part-II): 242h, 242.083h,242.25h, 242.333h, 243.333h, 244h, 246h, 248h, 252h on day 11.
AUEC is calculated by multiplying the ratio (Value at each time point/Ebase, unit of Vaue is [s] and Ebase is value [s] at baseline) by time. Therefore, Unit for AUEC2-12 is [h].</description>
        <time_frame>Day 4 and Day 11 (Part II); Time frame are provided in detail in the Description section</time_frame>
        <population>Pharmacodynamic set (PDS): The PDS comprised all subjects in the TS who provided at least 1 evaluable predose and 1 on-treatment pharmacodynamic observation.</population>
        <group_list>
          <group group_id="O1">
            <title>DE+Placebo_5m (Part II)</title>
            <description>Subject received a multiple oral doses of dabigatran etexilate 220 mg twice daily(b.i.d.) from Days 1 to 3 and once daily(q.d)on Day 4 and from Days 8 to 10 and once daily(q.d)on Day 11,followed with a single intravenous infusion of matching placebo to idarucizumab for 5min, approximately 2h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O2">
            <title>DE+1000mg_5m (Dose group5 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O3">
            <title>DE+2000mg_5m (Dose group6 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O4">
            <title>DE+4000mg_5m (Dose group7 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
          <group group_id="O5">
            <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
            <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
          </group>
        </group_list>
        <measure>
          <title>AUEC2-12</title>
          <description>Area under the effect curve over the time interval from 2 to 12h, AUEC2-12 on Days 4 and 11 for diluted thrombin time (dTT).
For dose groups 5 to 7(day4-Part-II): 74h, 74.5h, 75h, 76h, 78h, 80h, 82h, 84h on day 4. For dose groups 5 to 7(day11-Part-II): 242h, 242.083h, 242.167h, 242.5h, 243h, 244h, 246h, 248h, 250h, 252h. For dose groups 8(day4-Part-II): 74.5 h, 78 h, 84 h on day 4. For dose groups 8(day11-Part-II): 242h, 242.083h,242.25h, 242.333h, 243.333h, 244h, 246h, 248h, 252h on day 11.
AUEC is calculated by multiplying the ratio (Value at each time point/Ebase, unit of Vaue is [s] and Ebase is value [s] at baseline) by time. Therefore, Unit for AUEC2-12 is [h].</description>
          <population>Pharmacodynamic set (PDS): The PDS comprised all subjects in the TS who provided at least 1 evaluable predose and 1 on-treatment pharmacodynamic observation.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="2.30"/>
                    <measurement group_id="O2" value="18.0" spread="1.79"/>
                    <measurement group_id="O3" value="17.4" spread="4.00"/>
                    <measurement group_id="O4" value="15.5" spread="2.17"/>
                    <measurement group_id="O5" value="17.3" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="1.93"/>
                    <measurement group_id="O2" value="12.5" spread="1.74"/>
                    <measurement group_id="O3" value="11.2" spread="2.23"/>
                    <measurement group_id="O4" value="9.95" spread="0.206"/>
                    <measurement group_id="O5" value="10.0" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 13 weeks after the last drug administration, upto 98 days (Part-I) &amp; upto 108 days (Part-II)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo_5m (Part I)</title>
          <description>Subject received a single intravenous infusion of matching placebo to idarucizumab once daily for 5min on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Placebo_1h (Part I)</title>
          <description>Subject received a single intravenous infusion of matching placebo to idarucizumab once daily for 1h (hour) on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>BI1000mg_5m (Dose group1 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 1000mg for 5min on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>BI2000mg_5m (Dose group2 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 2000mg for 5min on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>BI4000mg_5m (Dose group3 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 4000mg for 5min on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>BI8000mg_1h (Dose group4 - Part I)</title>
          <description>Subject received a single intravenous infusion of idarucizumab 8000mg for 1h on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>DE+Placebo_5m (Part II)</title>
          <description>Subject received a multiple oral doses of dabigatran etexilate 220 mg twice daily(b.i.d.) from Days 1 to 3 and once daily(q.d)on Day 4 and from Days 8 to 10 and once daily(q.d)on Day 11,followed with a single intravenous infusion of matching placebo to idarucizumab for 5min, approximately 2h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="E8">
          <title>DE+Placebo+Placebo (Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d. from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of two doses of matching placebo to Idarucizumab for 5 min + 5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="E9">
          <title>DE+1000mg_5m (Dose group5 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 1000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="E10">
          <title>DE+2000mg_5m (Dose group6 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 2000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="E11">
          <title>DE+4000mg_5m (Dose group7 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with a single intravenously infusion of Idarucizumab 4000 mg for 5 min, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
        <group group_id="E12">
          <title>DE+2500mg+2500mg (Dose group8 - Part II)</title>
          <description>Subject received multiple oral doses of dabigatran etexilate 220 mg b.i.d.from Days 1 to 3 and q.d on Day 4 and from Days 8 to 10 and q.d on Day 11, followed with intravenously infusion of two doses of Idarucizumab 2500mg+2500mg for 5 min+5 min, with a 15 min infusion interval between two doses, approximately 2 h after the last dose of dabigatran etexilate on Day 11.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

